GSA Capital Partners’s Prelude Therapeutics PRLD Stock Holding History

GSA Capital Partners’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-75,161	Closed	-$108K	–	2000
2025 Q3	$108K	Buy	75,161 +3,783	+5%	+$3.79K	0.01%	1516
2025 Q2	$58K	Buy	+71,378	New	+$61.8K	﹤0.01%	1655
2023 Q4	–	Sell	-70,583	Closed	-$218K	–	1836
2023 Q3	$218K	Sell	70,583 -2,251	-3%	-$8.45K	0.02%	1246
2023 Q2	$328K	Buy	72,834 +25,220	+53%	+$151K	0.03%	1000
2023 Q1	$271K	Sell	47,614 -187	-0.4%	-$1.14K	0.03%	1084
2022 Q4	$289K	Sell	47,801 -6,372	-12%	-$40.8K	0.04%	952
2022 Q3	$358K	Buy	54,173 +17,547	+48%	+$118K	0.05%	816
2022 Q2	$191K	Buy	36,626 +13,425	+58%	+$68.3K	0.03%	1083
2022 Q1	$160K	Buy	+23,201	New	+$212K	0.02%	1222

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GSA Capital Partners's PRLD Position: Q4 2025 in Review

GSA Capital Partners sold out of Prelude Therapeutics (PRLD) in Q4 2025, closing a stake of 75,161 shares — an estimated $108K sold.

GSA Capital Partners first reported a position in PRLD in Q1 2022 and held it in 9 quarters. The position peaked at $358K in Q3 2022. 48 funds tracked by Wall St. Rank hold PRLD as of Q4 2025.

GSA Capital Partners reported no remaining Prelude Therapeutics position as of Q4 2025 after selling out during the quarter.
GSA Capital Partners sold 75,161 Prelude Therapeutics shares in Q4 2025, an estimated $108K.
GSA Capital Partners first reported a position in Prelude Therapeutics in Q1 2022 and held it in 9 quarters.
GSA Capital Partners's Prelude Therapeutics position peaked at $358K in Q3 2022.
48 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.